cd-47

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.

Anti-CD47 Antibody (B6.H12) is a chimeric mouse IgG1 κ antibody that specifically targets human CD47. The recommended isotype control for Anti-CD47 Antibody (B6.H12) is Mouse IgG1 kappa, Isotype Control.

Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an IgG1 monoclonal antibody specifically directed against mouse, rat, and human CD47/IAP. It effectively blocks CD47-mediated signaling to enhance macrophage phagocytic activity, promote immune cell infiltration into tissues, potentially interfere with wound healing processes, and support experimental investigations in oncology and inflammatory disease models, including but not limited to breast cancer research and studies of intestinal mucosal repair mechanisms.

Anti-CD47 (A4) antibody is a kind of antibody that can be used for Blocking, functional assays, FC and other related research.

Anti-CD47 (h4C1) antibody is a kind of antibody that can be used for activity assays, functional studies, binding affinity analysis, and other applications, serving as an essential tool in biological research.

Anti-CD47 Antibody (VxP037) is a kind of antibody that can be used for blocking and other related research.

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.